Home>Topics>Stocks>Myriad Genetics

Myriad Genetics MYGN

  1. All
  2. Commentary
  3. Headlines
    1. Myriad Genetics lowers fiscal Q1 guidance

      Headlines

      Fri, 17 Oct 2014

      Myriad Genetics (NASDAQ: MYGN ) lowers its fiscal Q1 guidance due to an increase in costs and turnaround ..... public comment period before a final coverage determination is made. MYGN is down 6% premarket on 4,300 shares. Post your comment!

    2. Myriad Encounters Minor Snag With MyRisk, Announces Positive Prolaris News

      Commentary

      Fri, 17 Oct 2014

      In conjunction with positive Prolaris news, Myriad Genetics announced that it is receiving myRisk samples more rapidly than anticipated, and that the subsequent increase in costs and turnaround

    3. Initial Uptake of Myriad's MyRisk Panel Test Remains Encouraging

      Commentary

      Wed, 13 Aug 2014

      Myriad Genetics reported fourth-quarter earnings Tuesday that were largely in line with our expectations as growth saw headwinds from revised

    4. Stock Picking Matters in the Current Market Climate

      Headlines

      Thu, 26 Jun 2014

      confident about right now? I discussed Myriad Genetics in January, and I still really like the ..... portfolios for more than a decade. Like Myriad Genetics , its share price has been somewhat volatile in 2014, but ..... 0.00 0.00 0.00 1.32 0.00 Myriad Genetics 3.18 1.90 3.56 4.02 0.00

    5. Myriad's Private Pricing Proves Durable in Third Fiscal Quarter

      Commentary

      Wed, 7 May 2014

      Myriad Genetics reported third-quarter earnings on Tuesday that were largely in line with our expectations, as private-payer pricing remained

    6. Chip Skinner on 1Q14: Looking at Current Long-Term Growth Plays

      Headlines

      Thu, 10 Apr 2014

      detractor in Value Plus, I’ve been very happy to see Myriad Genetics rebound nicely in 2014. Myriad is a molecular diagnostic company ..... 31/13 (%) RVP RLP Rockwood Holdings 1.77 0.00 Myriad Genetics 1.58 1.88 There can be no assurance that any of the

    7. CMS Restores BRACAnalysis Reimbursement

      Commentary

      Wed, 2 Apr 2014

      a surprising turn of events, the Centers for Medicare and Medicaid Services have posted a 52% increase in pricing for Myriad Genetics ’ BRACAnalysis test, from $1,438 to $2,184. As such, we plan to significantly raise our fair value estimate by

    8. From Barron’s, March 31, 2014 (Part 2)

      Commentary

      Sat, 29 Mar 2014

      attractively priced good growth stocks. Surprisingly, it now has many techs [ FB, MU, EBS, AAPL, CSCO ] and biotechs [ MYGN , QCOR, PDLI ]. These areas have contributed disproportionately to Index’s performance. In future, a boost may come from

    9. Myriad Encounters a Snag in its Litigation Efforts

      Commentary

      Tue, 11 Mar 2014

      Myriad Genetics announced Tuesday that its motion for preliminary injunctive relief in its case against Ambry Genetics has been denied, which

    10. Whitney George on 4Q13: Market Shows Resilience in Spite of Macro Headwinds

      Headlines

      Mon, 13 Jan 2014

      into 2014? Two stand out to me— Myriad Genetics and Cirrus Logic. In 2012, we held good ..... misperceptions surrounding Myriad and Cirrus. Myriad Genetics is a molecular diagnostic company specializing in genetic ..... 31/13 (%) RPR RLP RGV FUND RSV Myriad Genetics 1.88 1.67 2.25 2.52 2.64

    « Prev12345Next »
    Content Partners